Natera, Inc.

Is Natera, Inc. technically bullish or bearish?

As of October 3, 2025, Natera, Inc. shows a mildly bullish trend with strong weekly indicators and solid performance, having outperformed the S&P 500 over the past year and three years, despite mixed signals from different time frames.

As of 3 October 2025, the technical trend for Natera, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are bullish for both weekly and monthly periods, and the daily moving averages are also bullish. However, the weekly Dow Theory shows a mildly bearish stance, contrasting with the monthly Dow Theory, which is mildly bullish. <BR><BR>In terms of performance, Natera has outperformed the S&P 500 over the past year with a return of 31.22% compared to the S&P 500's 17.82%, and significantly over the past three years with a return of 262.28% versus 82.57%. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators and solid multi-period returns.

How big is Natera, Inc.?

As of Jun 18, Natera, Inc. has a market capitalization of $22.88 billion, with net sales of $1.83 billion and a net profit of -$189.76 million over the last four quarters. The company reported shareholder's funds of $1.20 billion and total assets of $1.69 billion as of Dec 24.

Market Cap: As of Jun 18, Natera, Inc. has a market capitalization of 22,878.38 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Natera, Inc. reported net sales of 1,831.00 million and a net profit of -189.76 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,195.42 million and total assets of 1,686.40 million.

What does Natera, Inc. do?

Natera, Inc. is a mid-cap diagnostics company specializing in genetic testing services, with recent net sales of $502 million and a net loss of $67 million. The company has a market cap of approximately $22.88 billion and does not pay dividends.

Overview:<BR>Natera, Inc. is a diagnostics company engaged in the discovery, development, and commercialization of genetic testing services within the Pharmaceuticals & Biotechnology industry, categorized as a mid-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 502 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -67 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 22,878.38 Million (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.73<BR>- Return on Equity: -15.31%<BR>- Price to Book: 18.46<BR><BR>Contact Details:<BR>- Address: 201 Industrial Rd Ste 410, SAN CARLOS CA: 94070-2396<BR>- Tel: ['1 650 2499090', '1 650 2499091']<BR>- Fax: 1 302 6745266<BR>- Website: http://www.natera.com

Should I buy, sell or hold Natera, Inc.?

Who are in the management team of Natera, Inc.?

As of March 2022, Natera, Inc.'s management team includes Dr. Matthew Rabinowitz (Executive Chairman), Mr. Steven Chapman (CEO), Mr. Jonathan Sheena (CTO), and several independent directors, including Roelof Botha and Dr. Monica Bertagnolli. This team provides strategic direction and governance for the company.

As of March 2022, the management team of Natera, Inc. includes the following individuals:<BR><BR>- Dr. Matthew Rabinowitz: Executive Chairman of the Board, Co-Founder<BR>- Mr. Steven Chapman: President, Chief Executive Officer, Director<BR>- Mr. Jonathan Sheena: Co-Founder, Chief Technology Officer, Director<BR>- Mr. Roelof Botha: Lead Independent Director<BR>- Mr. Roy Baynes: Independent Director<BR>- Dr. Monica Bertagnolli: Independent Director<BR>- Dr. Rowan Chapman: Independent Director<BR>- Mr. Todd Cozzens: Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.